Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 280
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03304028 | MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique | ||
| NCT06747572 | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease | ||
| NCT03486236 | A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects | ||
| NCT01262352 | Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation | ||
| NCT01275599 | Drug-Drug Interaction Study Between Telaprevir and Buprenorphine | ||
| NCT05329649 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | ||
| NCT05635110 | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants | ||
| NCT01467505 | An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients | ||
| NCT00251199 | VX-950 and Peginterferon for Hepatitis C | ||
| NCT02934698 | An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations | ||
| NCT01117012 | Rollover Study of VX-770 in Cystic Fibrosis Subjects | ||
| NCT06615570 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants | ||
| NCT01144936 | Study of VX-985 in Subjects With Chronic Hepatitis C | ||
| NCT05660538 | Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) | ||
| NCT03206749 | A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | ||
| NCT00457821 | Safety Study of Ivacaftor in Subjects With Cystic Fibrosis | ||
| NCT06460506 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | ||
| NCT05153317 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older | ||
| NCT01054573 | VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo | ||
| NCT03125395 | A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT04138589 | Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function | ||
| NCT06861413 | A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation | ||
| NCT06820307 | Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants | ||
| NCT05518734 | A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants | ||
| NCT00983853 | Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV | ||
| NCT01590407 | First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | ||
| NCT05865171 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment | ||
| NCT01768663 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects | ||
| NCT00535847 | A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy | ||
| NCT00758043 | A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response | ||
| NCT05653323 | A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants | ||
| NCT06226454 | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993 | ||
| NCT05579431 | A Phase 1, First-in-human Study of VX-634 | ||
| NCT01161537 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation | ||
| NCT01994486 | Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 | ||
| NCT03783286 | Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects | ||
| NCT03768089 | Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis | ||
| NCT01704521 | Viral Kinetics in HCV Clearance in Subjects With Hemophilia | ||
| NCT01581138 | VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C | ||
| NCT00336479 | Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C | ||
| NCT00420784 | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) | ||
| NCT03859531 | Gastrointestinal Study at Orkambi Therapy in CF Patients | ||
| NCT05312879 | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease | ||
| NCT02797132 | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | ||
| NCT07437105 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | ||
| NCT01501383 | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy | ||
| NCT05668741 | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | ||
| NCT03150719 | A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) | ||
| NCT04006873 | Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 | ||
| NCT01790100 | A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C |
